Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03064126 · ClinicalTrials.gov registry record · Phase 3
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
A Phase 3 study of Atherosclerosis and Peripheral Artery Disease, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT03064126 is a Phase 3 study of Atherosclerosis and Peripheral Artery Disease that has completed, run by Boston Scientific Corporation. The registered enrollment target is 440 participants, below the 1,059-participant average among 69 other Atherosclerosis trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT03064126, a Phase 3 study of Atherosclerosis and Peripheral Artery Disease, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA). Long Balloon substudy: To evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) Ranger™ Paclitaxel Coated Balloon in the 120, 150 and 200 mm lengths for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DEVICE RANGER™ Paclitaxel Coated Balloon
- PROCEDURE Standard Balloon Angioplasty
Study Locations (20)
Florida
- South Florida Vascular Associates - Coconut Creek
- North Florida Regional Medical Center - Gainesville
- Mount Sinai Medical Center - Miami Beach
- AdventHealth Orlando - Orlando
- AdventHealth Sebring - Sebring
Indiana
- St. Joseph Hospital - Fort Wayne
- Community Hospital - Munster
Minnesota
- Mercy Hospital - Coon Rapids
- United Heart and Vascular Clinic - Saint Paul
New Jersey
- Hackensack University Medical Center - Hackensack
- Jersey Shore University Medical Center - Neptune City
Alabama
- Thomas Hospital - Fairhope
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Connecticut
- The Vascular Experts - Stratford
Delaware
- Christiana Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2023-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03064126
The ClinicalTrials.gov registry entry for NCT03064126 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,059-participant average among 69 other Atherosclerosis trials with a reported enrollment target (58% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.
NCT03064126 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Indiana, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03064126 about?
NCT03064126 is a clinical study titled "RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty". To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA). Long Balloon substudy: To evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) Ranger™ Pac...
What is the current status of trial NCT03064126?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2017-03-02. Estimated completion is 2023-10-25.
What conditions does trial NCT03064126 study?
This clinical trial studies the following conditions: Atherosclerosis, Peripheral Artery Disease, Plaque, Atherosclerotic, Artery Diseases, Peripheral, Occlusive Arterial Disease.
What interventions are being tested in trial NCT03064126?
The interventions under investigation include: Paclitaxel (DRUG), RANGER™ Paclitaxel Coated Balloon (DEVICE), Standard Balloon Angioplasty (PROCEDURE).
Who is sponsoring clinical trial NCT03064126?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03064126 being conducted?
This trial has 20 study locations across Alabama, Colorado, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
COMPLETED · Phase 3
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
COMPLETED · Phase 3
-
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
COMPLETED · Phase 3
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.